Eli Lilly received notice from the U.S. Food and Drug Administration that its decision on the obesity candidate orforglipron will be postponed until April, extending the agency’s review by at least three months. Investors reacted swiftly, with trading volumes rising by over 40% on the day of the announcement. The delay gives competitors additional time to advance their pipelines and could push back Lilly’s expected launch timeline by a full quarter. Analysts now anticipate revised revenue forecasts for the obesity franchise, noting that orforglipron had been slated to contribute meaningful incremental sales starting in mid-2026.

In January, Lilly and Nvidia unveiled plans to allocate up to $1 billion over five years to build a joint research facility in California focused on AI-accelerated drug discovery. The lab will harness Nvidia’s latest Vera Rubin processors and Lilly’s proprietary biological datasets to train next-generation models for target identification and lead optimization. Site construction and equipment installation will begin in Q2, with initial compute operations expected by year-end. Leadership from both firms projects that integrating deep learning workflows could shorten early-stage candidate selection by as much as 30% and reduce preclinical attrition rates by 15 percentage points.

Lilly’s fourth-quarter results are forecast to reflect robust demand for its GLP-1 therapies Mounjaro and Zepbound. Supply chain enhancements expanded global patient access, while new formulary listings in major European markets helped offset anticipated price compression of 5–7%. Morgan Stanley projects combined quarterly volume growth of 45%, with year-over-year revenue growth in the obesity and diabetes portfolio exceeding 60%. Management has signaled that margin pressures will be contained through manufacturing efficiencies and ongoing cost-containment initiatives in marketing and distribution.